Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference slated to take place from March 17-19, 2021. In addition, Drysdale will participate … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care Psychedelics: Addressing the Global Mental Health Crisis. Drysdale’s presentation is scheduled to begin at 1:00 … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference”
Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading on the OTCQB, Cybin has achieved another important milestone on its path to advancing mental health care through evidenced-based therapeutics. … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Commences Trading on the OTCQB(R) Venture Market”
Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics … Continue reading “Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives”
Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB(R) Venture Market. Cybin will commence trading on the OTCQB under the symbol “CLXPF” at market open on March 8, 2021. “Listing on the OTCQB is another important milestone for … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Commence Trading on the OTCQB Venture Market”
Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work to quantify brain activity in real time during psychedelic … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences”
Pure Extract Technologies pursues study into psilocybin active treatments Study to extend for 250-day period, targeting a number of milestones The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, … Continue reading “Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments”
Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company focused on psychedelic pharmaceutical therapies, has scheduled a conference call and webcast for 10 a.m. ET on Wednesday, Feb. 17, 2021. Cybin CEO Doug Drysdale will conduct the call and webcast. The agenda for the call includes a review of the company’s financial results as well … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Announces Upcoming Conference Call, Webcast to Provide Business Update”
